Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

Clinical trial NCT01043874 · COMPLETED

Trial details

NCT number: NCT01043874
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase

Start date: 2009-12-01
Primary completion: 2013-12-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.